By Ludwig Burger
FRANKFURT (Reuters) -Roche’s third-quarter sales acquired a currency-adjusted 9%, defeating market assumptions, on greater prescriptions of once-monthly haemophilia shot Hemlibra and just recently introduced eye medication Vabysmo.
Group sales of 15.14 billion Swiss francs ($ 17.46 billion) exceeded an experts’ agreement quote of 14.9 billion francs, based upon LSEG information.
The Swiss drugmaker declared on Wednesday it anticipates development in 2024 modified profits per share in the “high single-digit range”, leaving out the result of money swings and resolution of tax obligation conflicts in 2023.
($ 1 = 0.8671 Swiss francs)
(Reporting by Ludwig Burger, Editing by Rachel More)
